[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470497":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":89,"collaborators":92,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":12,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":12,"overallStatus":39,"whyStopped":12,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard imaging monitored treatment","NO_INTERVENTION","Standard care + biomarkers, which are blinded until end of study.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention biomarker monitored treatment","EXPERIMENTAL","biomarker monitored treatment + imaging, which is blinded until end of study",[18],"Diagnostic Test: Biomarkers: Troponins and natriuretic peptides",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DIAGNOSTIC_TEST","Biomarkers: Troponins and natriuretic peptides","Biomarker monitored treatment with measurement of NT-proBNP and cTNT \u002F TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.",[14],[26],{"name":27,"affiliation":28,"role":29},"Ann Banke, MD PHD","Odense Universitetshospital","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},"Ann Banke, MD, PHD","CONTACT","+4526278303","Ann.Banke@rsyd.dk",[37,54,66,79],{"facility":38,"status":39,"city":40,"state":12,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Aalborg University Hospital","RECRUITING","Aalborg","9000","Denmark","DK",{"type":45,"coordinates":46},"Point",[47,48],9.9187,57.048,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":12,"phoneExt":12,"email":53},"Marie Louise Milo, MD","m.milo@rn.dk",{"facility":55,"status":39,"city":56,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Rigshospitalet","Copenhagen",{"type":45,"coordinates":58},[59,60],12.56553,55.67594,{"lat":60,"lon":59},[63],{"name":64,"role":33,"phone":12,"phoneExt":12,"email":65},"Maja Maraldo","Maja.Vestmoe.Maraldo@regionh.dk",{"facility":67,"status":68,"city":69,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Herlev University Hospital","NOT_YET_RECRUITING","Herlev",{"type":45,"coordinates":71},[72,73],12.43998,55.72366,{"lat":73,"lon":72},[76],{"name":77,"role":33,"phone":12,"phoneExt":12,"email":78},"Anne Polk, MD, PHD","anne.dyhl-polk@regionh.dk",{"facility":5,"status":39,"city":80,"state":12,"zip":81,"country":42,"countryCode":43,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Odense","5000",{"type":45,"coordinates":83},[84,85],10.38831,55.39594,{"lat":85,"lon":84},[88],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},{"type":29,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Ann Banke","Principal Investigator, Medical Doctor, PHD",[93,95,96],{"name":94,"class":6},"Aarhus University Hospital",{"name":38,"class":6},{"name":97,"class":6},"University of Copenhagen","100470497","imaging-versus-cardiac-biomarker-monitored-her2-directed-therapy-in-patients-with-breast-cancer-100470497",false,"NCT05406635","Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer","A National Randomized Non-inferiority Trial: Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer","HER2BIC","Inclusion Criteria:\n\n* Patients with non-metastatic HER2 positive breast cancer\n* Scheduled for standard chemotherapy and HER2 directed therapy with trastuzumab +\u002F- pertuzumab\n* Age \\> 18 years\n* Sinus rhythm on ECG\n* NT-proBNP below125 pg\u002Fml\n* Troponin below threshold limit value\n* LVEF \\> 55% by MUGA scan or an echocardiogram\n\nExclusion Criteria:\n\n* Contra indications for cardiac magnetic resonance imaging (CMRI)\n* Chronic obstructive pulmonary disease with FEV1 \\\u003C80 % of predicted","FEMALE","18 Years","90 Years",{"count":110,"type":111},220,"ESTIMATED","INTERVENTIONAL",[114],"NA","Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose of this study is to evaluate, if biomarkers can replace imaging based examinations of myocardial function during HER2 directed therapy.",[117,118],"Cardiotoxicity","HER2-positive Breast Cancer","2025-04-04",{"date":121,"type":122},"2025-04-08","ACTUAL",{"date":124,"type":122},"2021-10-01",{"date":126,"type":111},"2027-09-01",{"name":5,"class":6},4]